ASTRANA HEALTH INC (ASTH) Fundamental Analysis & Valuation

NASDAQ:ASTH • US03763A2078

Current stock price

24.48 USD
+0.46 (+1.92%)
At close:
24.48 USD
0 (0%)
After Hours:

This ASTH fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. ASTH Profitability Analysis

1.1 Basic Checks

  • ASTH had positive earnings in the past year.
  • ASTH had a positive operating cash flow in the past year.
  • ASTH had positive earnings in each of the past 5 years.
  • In the past 5 years ASTH always reported a positive cash flow from operatings.
ASTH Yearly Net Income VS EBIT VS OCF VS FCFASTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

1.2 Ratios

  • ASTH has a Return On Assets of 1.01%. This is comparable to the rest of the industry: ASTH outperforms 51.00% of its industry peers.
  • ASTH has a Return On Equity of 2.89%. This is comparable to the rest of the industry: ASTH outperforms 57.00% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 3.75%, ASTH is in line with its industry, outperforming 47.00% of the companies in the same industry.
  • ASTH had an Average Return On Invested Capital over the past 3 years of 5.51%. This is below the industry average of 8.86%.
Industry RankSector Rank
ROA 1.01%
ROE 2.89%
ROIC 3.75%
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ASTH Yearly ROA, ROE, ROICASTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • The Profit Margin of ASTH (0.71%) is comparable to the rest of the industry.
  • ASTH's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 3.08%, ASTH is in line with its industry, outperforming 54.00% of the companies in the same industry.
  • ASTH's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 10.73%, ASTH is doing worse than 73.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ASTH has declined.
Industry RankSector Rank
OM 3.08%
PM (TTM) 0.71%
GM 10.73%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
ASTH Yearly Profit, Operating, Gross MarginsASTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. ASTH Health Analysis

2.1 Basic Checks

  • ASTH has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ASTH has more shares outstanding
  • Compared to 5 years ago, ASTH has more shares outstanding
  • Compared to 1 year ago, ASTH has a worse debt to assets ratio.
ASTH Yearly Shares OutstandingASTH Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
ASTH Yearly Total Debt VS Total AssetsASTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • ASTH has an Altman-Z score of 2.40. This is not the best score and indicates that ASTH is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ASTH has a Altman-Z score (2.40) which is comparable to the rest of the industry.
  • ASTH has a debt to FCF ratio of 9.94. This is a negative value and a sign of low solvency as ASTH would need 9.94 years to pay back of all of its debts.
  • The Debt to FCF ratio of ASTH (9.94) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 1.27 is on the high side and indicates that ASTH has dependencies on debt financing.
  • The Debt to Equity ratio of ASTH (1.27) is worse than 64.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF 9.94
Altman-Z 2.4
ROIC/WACC0.49
WACC7.71%
ASTH Yearly LT Debt VS Equity VS FCFASTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 1.40 indicates that ASTH should not have too much problems paying its short term obligations.
  • ASTH has a Current ratio (1.40) which is comparable to the rest of the industry.
  • ASTH has a Quick Ratio of 1.40. This is a normal value and indicates that ASTH is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of ASTH (1.40) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
ASTH Yearly Current Assets VS Current LiabilitesASTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. ASTH Growth Analysis

3.1 Past

  • ASTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -48.31%.
  • ASTH shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -14.74% yearly.
  • Looking at the last year, ASTH shows a very strong growth in Revenue. The Revenue has grown by 56.39%.
  • ASTH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 35.87% yearly.
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%

3.2 Future

  • Based on estimates for the next years, ASTH will show a very strong growth in Earnings Per Share. The EPS will grow by 54.34% on average per year.
  • Based on estimates for the next years, ASTH will show a quite strong growth in Revenue. The Revenue will grow by 9.59% on average per year.
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ASTH Yearly Revenue VS EstimatesASTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B 5B
ASTH Yearly EPS VS EstimatesASTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. ASTH Valuation Analysis

4.1 Price/Earnings Ratio

  • ASTH is valuated quite expensively with a Price/Earnings ratio of 53.22.
  • Compared to the rest of the industry, the Price/Earnings ratio of ASTH is on the same level as its industry peers.
  • ASTH's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.50.
  • ASTH is valuated rather expensively with a Price/Forward Earnings ratio of 19.40.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ASTH indicates a somewhat cheap valuation: ASTH is cheaper than 61.00% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.67, ASTH is valued at the same level.
Industry RankSector Rank
PE 53.22
Fwd PE 19.4
ASTH Price Earnings VS Forward Price EarningsASTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASTH.
  • Based on the Price/Free Cash Flow ratio, ASTH is valued a bit cheaper than the industry average as 79.00% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.59
EV/EBITDA 12.49
ASTH Per share dataASTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • ASTH's earnings are expected to grow with 87.86% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y103.85%
EPS Next 3Y87.86%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ASTH Dividend Analysis

5.1 Amount

  • No dividends for ASTH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ASTH Fundamentals: All Metrics, Ratios and Statistics

ASTRANA HEALTH INC

NASDAQ:ASTH (3/25/2026, 4:30:02 PM)

After market: 24.48 0 (0%)

24.48

+0.46 (+1.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-02
Earnings (Next)05-06
Inst Owners59.72%
Inst Owner ChangeN/A
Ins Owners9.87%
Ins Owner Change0.91%
Market Cap1.21B
Revenue(TTM)3.18B
Net Income(TTM)22.49M
Analysts84.71
Price Target36.38 (48.61%)
Short Float %7.49%
Short Ratio5.13
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP35.06%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-43.4%
Min EPS beat(2)-97.78%
Max EPS beat(2)10.99%
EPS beat(4)1
Avg EPS beat(4)-44.97%
Min EPS beat(4)-97.78%
Max EPS beat(4)10.99%
EPS beat(8)4
Avg EPS beat(8)-50.25%
EPS beat(12)7
Avg EPS beat(12)-23.47%
EPS beat(16)10
Avg EPS beat(16)-9.93%
Revenue beat(2)1
Avg Revenue beat(2)-0.74%
Min Revenue beat(2)-1.62%
Max Revenue beat(2)0.15%
Revenue beat(4)2
Avg Revenue beat(4)-1.11%
Min Revenue beat(4)-3.56%
Max Revenue beat(4)0.57%
Revenue beat(8)5
Avg Revenue beat(8)0.83%
Revenue beat(12)7
Avg Revenue beat(12)0.78%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.13%
PT rev (3m)-11.39%
EPS NQ rev (1m)29.91%
EPS NQ rev (3m)29.91%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)-8.28%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.19%
Revenue NY rev (1m)0.05%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 53.22
Fwd PE 19.4
P/S 0.38
P/FCF 11.59
P/OCF 10.57
P/B 1.55
P/tB N/A
EV/EBITDA 12.49
EPS(TTM)0.46
EY1.88%
EPS(NY)1.26
Fwd EY5.16%
FCF(TTM)2.11
FCFY8.63%
OCF(TTM)2.32
OCFY9.46%
SpS64.32
BVpS15.75
TBVpS-7.22
PEG (NY)0.31
PEG (5Y)N/A
Graham Number12.77
Profitability
Industry RankSector Rank
ROA 1.01%
ROE 2.89%
ROCE 6.12%
ROIC 3.75%
ROICexc 5.12%
ROICexgc 160.26%
OM 3.08%
PM (TTM) 0.71%
GM 10.73%
FCFM 3.28%
ROA(3y)3.57%
ROA(5y)4.69%
ROE(3y)6.27%
ROE(5y)8.46%
ROIC(3y)5.51%
ROIC(5y)6.5%
ROICexc(3y)8.45%
ROICexc(5y)10.18%
ROICexgc(3y)90.21%
ROICexgc(5y)71.8%
ROCE(3y)9%
ROCE(5y)10.61%
ROICexgc growth 3Y64.68%
ROICexgc growth 5Y30.22%
ROICexc growth 3Y-25.1%
ROICexc growth 5Y-14.45%
OM growth 3Y-30.31%
OM growth 5Y-23.43%
PM growth 3Y-43.64%
PM growth 5Y-33.68%
GM growth 3Y-14.93%
GM growth 5Y-13%
F-Score4
Asset Turnover1.43
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF 9.94
Debt/EBITDA 6.89
Cap/Depr 22.09%
Cap/Sales 0.32%
Interest Coverage 2.14
Cash Conversion 79.65%
Profit Quality 464.67%
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z 2.4
F-Score4
WACC7.71%
ROIC/WACC0.49
Cap/Depr(3y)70.53%
Cap/Depr(5y)90.42%
Cap/Sales(3y)0.92%
Cap/Sales(5y)1.45%
Profit Quality(3y)210.81%
Profit Quality(5y)167.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-48.31%
EPS 3Y-24.29%
EPS 5Y-14.74%
EPS Q2Q%180%
EPS Next Y174.35%
EPS Next 2Y103.85%
EPS Next 3Y87.86%
EPS Next 5Y54.34%
Revenue 1Y (TTM)56.39%
Revenue growth 3Y40.62%
Revenue growth 5Y35.87%
Sales Q2Q%42.89%
Revenue Next Year25.65%
Revenue Next 2Y18.01%
Revenue Next 3Y13.68%
Revenue Next 5Y9.59%
EBIT growth 1Y9.82%
EBIT growth 3Y-2%
EBIT growth 5Y4.04%
EBIT Next Year220.54%
EBIT Next 3Y60.15%
EBIT Next 5Y39.29%
FCF growth 1Y136.58%
FCF growth 3Y20.86%
FCF growth 5Y18.35%
OCF growth 1Y119.54%
OCF growth 3Y11.74%
OCF growth 5Y19.94%

ASTRANA HEALTH INC / ASTH Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASTRANA HEALTH INC?

ChartMill assigns a fundamental rating of 4 / 10 to ASTH.


What is the valuation status of ASTRANA HEALTH INC (ASTH) stock?

ChartMill assigns a valuation rating of 4 / 10 to ASTRANA HEALTH INC (ASTH). This can be considered as Fairly Valued.


How profitable is ASTRANA HEALTH INC (ASTH) stock?

ASTRANA HEALTH INC (ASTH) has a profitability rating of 3 / 10.


What is the valuation of ASTRANA HEALTH INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRANA HEALTH INC (ASTH) is 53.22 and the Price/Book (PB) ratio is 1.55.


Can you provide the financial health for ASTH stock?

The financial health rating of ASTRANA HEALTH INC (ASTH) is 3 / 10.